WHO ARE BIOCURE'S INVESTORS?
WHERE DOES BIOCURE STAND TODAY?
WHO ARE BIOCURE'S MANAGEMENT?

Who are BioCure's Investors?

Our first round of investment, completed in September 1999, was made by the original supporters of the seed project within CIBA Vision:

:::	CIBA Vision, Switzerland and USA
:::	Novartis Venture Fund, Switzerland
:::	CRCERT/CSIRO, Australia
:::	Institute for Eye Research, Australia

Where does BioCure stand today?

BioCure continues to reinvest its financial returns from its license to and its manufacturing collaboration with Biocompatibles UK Ltd.

By restricting its focus to R&D and manufacturing, BioCure has been able to continue to partner with leading commercial and research partners in the therapeutic areas of spine and orthopedic and wound care. These programs target short and medium-term regulatory approvals.

We are seeking to expand collaborations in these sectors.

Additionally, we have recently formed a Swiss subsidiary company, BioCure (Schweiz) GmBH, which is focused on the development of our intellectual capital in the exciting area of nanotechnology. We are actively seeking new collaborations and, potentially, new investors as we develop a detailed product pipeline.

Who are BioCure's management?

We have an experienced management team supported by highly trained and innovative researchers in the areas of polymer science, cell biology, engineering, manufacturing and quality control.

Mr. Andrew Maslaveckas is CEO, President, co-founder and Operating Officer of BioCure responsible for all of BioCure’s research and commercial operations. Mr. Maslaveckas has over 30 years of experience in managing and building both consumer and professional health care companies.

Prior to the establishment of BioCure, Mr. Maslaveckas, as Head of New Growth Businesses at CIBA Vision, was primarily responsible for identifying the commercial and market rationale for BioCure's spin-off from Novartis.

Joining Ciba Vision in 1993, Mr. Maslaveckas, as Global Head of Contact Lenses, was charged with developing and implementing an aggressive strategy to build a significant presence in the disposable contact lens segment and to grow CIBA Vision's contact lens profitability and market share in the contact lens business in the face of strong competition from Johnson & Johnson and Bausch & Lomb. During his tenure, CIBA Vision's sales revenues increased over 30% per annum and approached $500 million with excellent returns on sales and capital.

Prior to 1993, Mr. Maslaveckas worked for 14 years with Johnson & Johnson in a number of executive positions in the consumer and professional businesses.

In 1989, he joined Vistakon UK in its first year as Managing Director responsible for relaunching its ACUVUE* disposable contact lens franchise following initial revenue and financial disappointments. Mr. Maslaveckas initiated a highly successful campaign which culminated in Vistakon achieving the #1 position in the market in his second year and building the business to J&J's largest revenue brand in the UK through aggressive consumer and professional initiatives. In 1991, Mr. Maslaveckas added responsibilities for Vistakon Germany and later joined both the J&J UK Board and was Vistakon's representative on the European Management Committee of J&J's Professional segment.

In 1985, Mr. Maslaveckas, following a regional assignment in Morocco, was named as the first Managing Director of the company and charged with the establishment of a sales, marketing and manufacturing presence and infrastructure. During his six years in Morocco, the company became the #1 market leader in the baby toiletries, sanitary protection and shampoo markets through aggressive and innovative commercial programs. Latterly, the company assumed responsibilities for J&J's professional and pharmaceutical franchises.

Mr. Maslaveckas joined J&J in the UK as an Area Manager and subsequently a Regional Manager in its sales and marketing department charged with P&L responsibility for distributor territories in Southern Europe, Africa and the Middle East.

Mr. Maslaveckas graduated M.A. (Hons) in French and Russian from the University of Glasgow in 1977.

Dr. Fiona Carney is Clinical and Project Director at BioCure Inc.

Dr Carney studied her PhD at the University of New South Wales in Sydney, Australia. The subject of her thesis was the biocompatibility of new ocular devices. Throughout her years in the medical device industry she has also gained her Diploma in Project Management and been elected a Fellow in the British Contact Lens Association.

Dr Carney left Australia in 1998 to take a Postdoctoral position at The Medical Center at Louisiana State University with Dr Jean Jacob. It was here that Dr Carney studies the affect and residence of various ocular medications on severe dry eye as well as identifying any distinct difference in tear protein profile between the normal and dry eye state.

In 1999, Dr Carney then took another Postdoctoral position at Ciba Vision in Atlanta Georgia where she studied novel antimicrobial peptides and the use of various surface polymer chemistry techniques to covalently attach without the loss of biological function.

After 18 months Dr Carney became a senior Scientist at Ciba Vision in which she investigated the use of daily disposable contact lenses as a collection device for ex vivo diagnostics. Clinical correlations and feasibility of the device was shown for the detection of steroid hormones for ovulation detection as well as glucose correlations for the diagnosis of diabetes and diabetic retinopathy. In doing this Dr Carney was responsible for the design of unique and specialized animal studies to ensure safety and efficacy of the products.

Throughout Dr Carney’s years as a Principal Scientist at Ciba Vision she studied the binding affinity of various tear film proteins dependent on surface chemistry. These findings translated to the additions of various polymers to contact lenses and storage solutions to decrease protein adsorption to lenses and increase vision clarity and comfort. Dr Carney also served on the Corporate Advisory Board for the Tear Film and Ocular Surface Society and a reviewer for the Investigative Ophthalmology and Visual Science journal. She also has 4 issued patents and 8 patent applications, amongst various publications and presentations.

Dr Carney joined BioCure Inc. in October 2007 to become Project Director for the development of a medical device in the orthopedic area. Dr Carney is also responsible for all preclinical studies performed at BioCure Inc.

Dr. Thomas Hirt is Vice President of Research and Development and General Manager of BioCure (Schweiz) GmbH.

Dr. Hirt joined Ciba Geigy AG in 1995 working at its Central Research Unit in Basel, Switzerland. After one year, he transferred to Ciba Vision in Atlanta, USA as a Senior Scientist working primarily on developing new polymeric materials for extended wear contact lenses. In this context, he also synthesized amphiphilic triblock copolymers, that were used to make the first hollow, polymeric nanovesicles in water.

After 3 years at Ciba Vision, he moved back to Switzerland to head up the Research and Development and New Business Development efforts at SEFAR, Printing Division. During the 8 years at SEFAR AG, as a member of the Divisional Management, he implemented state of the art R&D procedures, increased sales of new products from annual growth in the low single digits to high double digits percentages. At SEFAR, he gained experience in contract negotiations, business processes, product development and project and technology management.

Dr. Hirt joined BioCure in January 2007 to lead the start-up of BioCure Switzerland. As an original inventor, he is responsible for the business and product development of the hollow, polymeric nanovesicles. He is also responsible for the corporate materials development group.

Dr. Hirt is a graduate from ETH in Zurich in Technical Chemistry, conducted his PhD in polymer science and holds a Diploma in Marketing. The subject of his PhD is the synthesis and characterization of new degradable polymers for medical applications.

Sameer Shums is the QA/RA Manager at BioCure, Inc.

Mr. Shums is an engineer with over 10 years of experience developing devices for a variety of medical applications. Mr. Shums started as an R&D Engineer with Novoste Corp. developing catheter-based delivery systems for their vascular brachytherapy device for the treatment of in-stent restenosis.

Following Novoste, Mr. Shums worked for CardioMEMS, Inc., providing Operations support for the development and manufacture of the 1st and 2nd generations of the EndoSure® Wireless Sensor for aneurysms. He worked at CardioMEMS for 3+ years before joining BioCure, Inc. as a Project Director.

Mr. Shums joined BioCure in July 2007 and assumed responsibility for the development of the GelSpray™ in situ forming hydrogel dressing, and the next generation applications intended to provide drug delivery capability. He is also responsible for engineering activities at BioCure including test method development and the design of delivery systems for the various polymers. Recently, Mr. Shums has assumed responsibilities for Quality Assurance & Regulatory Affairs for BioCure.
Mr. Shums graduated from the University of Miami with a BS in Biomedical Engineering with a mechanical concentration and from the University of Georgia with a MBA.

Please contact us if you have any questions. We'd be happy to provide you with more information.